Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma

In the era of personalized treatment in multiple myeloma, high-risk patients must be accurately identified. The International Myeloma Working Group recommends using the Revised International Staging System (R-ISS) to pick out high-risk patients. The main purpose of our work was to explore the hetero...

Descripción completa

Detalles Bibliográficos
Autores principales: Schavgoulidze, Anaïs, Lauwers-Cances, Valérie, Perrot, Aurore, Cazaubiel, Titouan, Chretien, Marie-Lorraine, Moreau, Philippe, Facon, Thierry, Leleu, Xavier, Karlin, Lionel, Stoppa, Anne-Marie, Decaux, Olivier, Belhadj, Karim, Arnulf, Bertrand, Mohty, Mohamad, Mariette, Clara, Fohrer-Sonntag, Cécile, Lenain, Pascal, Marolleau, Jean-Pierre, Tiab, Mourad, Araujo, Carla, Orsini-Piocelle, Frédérique, Jaccard, Arnaud, Roussel, Murielle, Benboubker, Lotfi, Eveillard, Jean-Richard, Dib, Mamoun, Divoux, Marion, Attal, Michel, Avet-Loiseau, Hervé, Corre, Jill
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
ARTICLE - Plasma Cell Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153521/
https://www.ncbi.nlm.nih.gov/pubmed/36172814
http://dx.doi.org/10.3324/haematol.2021.280566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153521/
https://www.ncbi.nlm.nih.gov/pubmed/36172814
http://dx.doi.org/10.3324/haematol.2021.280566

Ejemplares similares